Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market By Different Cancers
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
The significant rise in the burden of cancer has surged the demand of targeted therapies in last few years. As targeted therapies target the root line cause of the disease, it helps in overcoming the limitations associated with conventional therapies. There has been shift in focus of healthcare providers towards targeted therapies as they have shown success in the management of advanced stages of cancer. However, drug resistance is one of the major limitations of such targeted therapies which have propelled the further research and development activities.
Combination cancer immunotherapy represents a new paradigm of targeted cancer therapy which works by combining two or more drugs which works in additive manner and overcomes the limitation of drug resistance. The first combinational immunotherapy was approved in 2015 by US FDA. The combination of nivolumab and ipilimumab was approved for the management of BRAF mutated metastatic melanoma. Further in 2016, the novel combination was approved across all BRAF status. Since then, there has been rapid approval of novel immunotherapeutic approaches in combination with other approaches, which have emerged out to be new era of targeted cancer therapy.
The combination cancer immunotherapy has gained significant interest from pharmaceutical giants owing to their novel mechanism of action and conferred advantages in terms of specificity and targetability. Huge investments are being done by pharmaceutical companies to drive the research and development in this segment. Furthermore, several key players in the market have also entered into collaboration or partnerships to drive the research and development in this segment. Recently in 2022, Transgene and PersonGen Biotherapeutics announced strategic research collaboration to evaluate the safety and efficacy of combination therapy associating PersonGen’s TAA06 CAR-T cell injection with intravenous (IV) administration of an armed oncolytic virus, from Transgene’s Invir.IO™ platform, in solid tumors including pancreatic cancer and brain glioma. The collaboration aims to demonstrate the combination’s likely synergistic mechanisms to potentiate CAR-T cell therapy.
Another, ImmVira has entered into cooperation agreement with Roche to conduct clinical studies in US evaluating the safety and efficacy of ImmVira’s MVR-T3011 and Roche’s MEK inhibitor cobimetinib. MVR-T3011, ImmVira’s proprietary 3 in 1 oncolytic herpes simplex virus (oHSV) is novel genetically engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in cancer cells. The incorporation of two latest and well validated exogeneous genes, PD-1 antibody and IL-12, further enhances immune response in tumor microenvironment.
In addition to this, several companies have also received investigational new drug (IND) clearance to initiate their clinical trials in this segment. Recently in 2022, US FDA cleared IND application to initiate phase-I/II BEXMAB study of bexmarilimab (FP-1305) in combination with standard of care in patients with relapsed acute myeloid leukemia, myelodsyplastic syndrome, or chronic myeloid leukemia. Bexmarilimab is an investigational anti-common lymphatic endothelial and vascular endothelial receptor 1 (Clever-1) antibody which has the potential to provide permanent immune stimulation for cancers by targeting myeloid cell function. Further, MHRA in UK has accepted the clinical trial application of PDS Biotechnology to allow expansion of its VERSATILE-002 study of PDS0101 in combination with pembrolizumab in patients with HPV related cancers.
As per our report findings, the global combination cancer immunotherapy market is expected to surpass US$ 15 Billion by 2028. The large number of ongoing clinical trials and their encouraging results is propelling the growth of market. It is analyzed that more than 3000 clinical trials are ongoing which are evaluating more than 400 drugs in the market, thus suggesting promising role of combination cancer immunotherapy in the targeted cancer therapy market. The major key players in combination cancer immunotherapy market are Asher Biotherapeutics, Merck, Eli Lilly, GlaxoSmithKline, Sanofi, Pfizer, Amgen, amongst others.